NCT03906058View on ClinicalTrials.gov

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

February 27, 2021

Study Completion Date

April 30, 2022

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

Anlotinib

All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .

Trial Locations (1)

510000

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT03906058 - Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy | Biotech Hunter | Biotech Hunter